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Abstract
Focal segmental glomerulosclerosis (FSGS) is a histological lesion with many causes including 
inherited genetic defects with significant proteinuria being the predominant clinical finding at 
presentation. Mutations in COL4A3 and COL4A4 are known to cause Alport syndrome, thin 
basement membrane nephropathy, and to result in pathognomonic glomerular basement membrane 
findings. Secondary FSGS is known to develop in classic Alport Syndrome at later stages of the 
disease. Here, we present seven families with rare or novel variants in COL4A3 or COL4A4 (six 
with single and one with two heterozygous variants) from a cohort of 70 families with a diagnosis 
of hereditary FSGS. The predominant clinical findings at diagnosis were proteinuria associated 
with hematuria. In all seven families, there were individuals with nephrotic range proteinuria with 
histologic features of FSGS by light microscopy. In one family, electron microscopy showed thin 
glomerular basement membrane, but four other families had variable findings inconsistent with 
classical Alport nephritis. There was no recurrence of disease after kidney transplantation. 
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Families with COL4A3 and COL4A4 variants that segregated with disease represent 10% of our 
cohort. Thus, COL4A3 and COL4A4 variants should be considered in the interpretation of next-
generation sequencing data from such patients. Furthermore, this study illustrates the power of 
molecular genetic diagnostics in the clarification of renal phenotypes.
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Introduction
Focal segmental glomerulosclerosis (FSGS) is the third leading cause of end-stage kidney 
disease (ESKD) in the USA and its incidence is estimated at 23 per million population1. 
Current treatments for primary FSGS frequently fail to induce remission and are poorly 
tolerated2,3. Proteinuria is frequently the earliest clinical manifestation of FSGS and can 
predate the development of renal failure by months or years4. A number of podocyte-
specific gene mutations have been shown to cause familial FSGS including TRPC6, ACTN4, 
WT1, CD2AP, INF2, NPHS1, NPHS2 and PLCE15-12. This enrichment of single gene 
causes of FSGS in the podocyte suggests that this cell plays a central role in the 
pathogenesis of proteinuria and FSGS. However, the podocyte is part of a complex 
glomerular filtration barrier that is responsible for the permselectivity of the glomerulus. 
Defects in the glomerular basement membrane (GBM) can cause Alport Syndrome (AS) and 
thin basement membrane nephropathy (TBMN). AS consists of a triad of progressive renal 
failure, hearing loss and ocular abnormalities and occurs due to mutations in COL4A5 in 
85% of cases13. Classic X-linked disease presents in childhood with microscopic or gross 
hematuria and progression to ESKD in the second to third decade of life13. Autosomal 
dominant and autosomal recessive AS due to mutations in COL4A3 and COL4A4 genes are 
less common and their phenotype is more variable when compared with X-linked 
disease14-17. One of the variable clinical manifestations that have been reported in cohorts of 
patients with autosomal AS is the presence of proteinuria and changes consistent with FSGS 
on kidney biopsy. These changes often occur late in the course of the disease and are 
typically reported as secondary changes due to the primary glomerular basement membrane 
defect induced by abnormal collagen. It is therefore conceivable that some patients with 
collagen(IV) related kidney disease may phenocopy both idiopathic and familial FSGS. To 
the best of our knowledge, there are no studies looking at the prevalence of rare variants in 
COL4A3 and COL4A4 in a cohort of patients with a diagnosis of familial FSGS.
In this study, we performed whole-exome sequencing (WES), podocyte-exome sequencing 
(PES) or direct sequencing on 70 families with a diagnosis of familial FSGS. We found that 
7 out of 70 families (10%) in our cohort have rare variants in COL4A3 and COL4A4. Based 
on these findings we posit that rare variants in COL4A3 and COL4A4 are common in a 
cohort of patients with familial FSGS and some of these variants may be disease causing. 
Furthermore, our findings illustrate the role of molecular diagnosis in accurate disease 
classification.
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We identified 70 families with familial FSGS of unknown cause. This cohort included our 
index family, Family DUK6696.
Index kindred; Family DUK6696
Three female siblings presented with nephrotic range proteinuria and hematuria between 8 
and 12 years of age. The oldest sibling had a biopsy at diagnosis, which showed classical 
features of FSGS (Figure 1). She progressed to ESKD within four years. No affected 
individuals have been transplanted (Table 1). The two parents are well and are not known to 
have any kidney disease. The referring physician made a diagnosis of familial FSGS and the 
family was referred to our group for genetic studies. Whole exome sequencing (WES) was 
performed on this family and analyzed using our filtering algorithm as described in 
supplementary Figure 1. We did not find any disease causing mutations in any known FSGS 
genes, however; we identified a novel compound heterozygous truncating variants in trans 
(E131Xfs151 and Q936X) in COL4A3 (Figure 2). These two novel variants were the only 
two variants that segregated with disease in this family.
Analysis of a familial FSGS cohort for COL4A3 and COL4A4 variants
Based on these findings, a directed search for rare variants in COL4A3 and COL4A4 was 
undertaken in 62 additional families that were referred to us with familial FSGS using next 
generation sequencing (NGS: WES and PES). Furthermore, we performed direct sequencing 
of all the exons and the exon/intron borders in COL4A3 and COL4A4 in seven families that 
did not have NGS data. We identified an additional six families with rare or novel COL4A3 
or COL4A4 variants that segregated with disease. Thus, seven families out of 70 (10%) in 
this cohort were found to have rare or novel COL4A3 or COL4A4 variants. Of these, only 
the index family had a compound heterozygous variant, the other six families had a single 
heterozygous variant. The phenotypes of these seven families are shown in Table 1. The 
biopsy diagnosis of FSGS was made based on 1) the presence of focal, segmental areas of 
glomerular sclerosis, often with associated hyalinosis and adhesions of sclerotic tufts to 
Bowman's capsule, 2) the presence of some degree of podocyte foot process effacement as 
assessed by electron microscopy, and 3) the absence of immune deposits or other defined 
causes of glomerulonephritis as assessed by immunofluorescence or electron microscopy. 
Specific immunofluorescent staining for alpha chains of type IV collagen was not 
performed. A representative biopsy from one of these seven families, Family DUK6534, is 
shown in Figure 3. Light microscopy (LM) showed segmental sclerosis with hyalinosis and 
adhesion to Bowman's capsule. Electron microscopy (EM) showed localized effacement of 
podocyte foot processes and localized areas of basement membrane denudation with loss of 
podocyte cytoplasm. Glomerular basement membranes are slightly irregular but they have 
normal thickness with no lamination. Supplementary Figure 2 shows pedigrees for the 
additional six families.
Genotype phenotype correlation
There are three families (Families DUK6534, DUK6630 and DUK6527) with missense 
variants at glycine residues in the collagenous domain of α3 or α4 collagen(IV), two 
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families (Families DUK6531 and DUK6585) with missense variants in the NC1 domains 
and two families (Families DUK6696 and DUK6669) with truncating variants in COL4A3 
and COL4A4 (Table 2). There is intra-family and inter-family variation in phenotype among 
the seven families (Table 1). However, at least one individual in each of the three Families, 
DUK6696, DUK6585 and DUK6669 presented with nephrotic range proteinuria and/or 
FSGS on renal biopsy in the first two decades of life. The family with the compound 
heterozygous truncating variant had early onset disease with nephrotic range proteinuria 
compared with the families with single heterozygous variants. The families with missense 
mutations in the NC1 domain of α3 collagen(IV) had no obvious difference in phenotype or 
histology compared to the families with glycine variants. Electron microscopy (EM) data 
was available in five of the seven families with collagen (IV) variants (Families DUK6534, 
DUK6585, DUK6527, DUK6630 and DUK6669). Thin glomerular basement membrane 
(GBM) was found in Family DUK6630 with an average thickness of 230nm. In Families 
DUK6527, DUK6585, and DUK6669 the GBMs were thickened and wrinkled. In one 
family, Family DUK6534, the GBM thickness and architecture were normal. Basement 
membrane splitting, lamellation and basket weaving typical of AS were absent in all of the 
EM images evaluated. In those individuals who received a kidney transplant there was no 
recurrence of disease. The only obvious phenotypic difference between the families with 
COL4A4 variants (Families DUK6527, DUK6669) and those with COL4A3 variants was the 
presence of hearing loss in the COL4A3 families. In all the families with hearing loss, 
history of hearing loss was established post priori after COL4A3 variants were identified.
COL4A3 and COL4A4 variant locations
The COL4A3 and COL4A4 variants did not cluster in any particular region of either gene. 
Specifically, no variants lie in the KRGDS motif in the α3 chain. This motif in the α3 chain 
of collagen(IV) has been shown to bind to integrin proteins on human podocytes in vitro18. 
Missense variants were present in the collagenous domains and NC1 domains of COL4A3 
and COL4A4. The truncating variants were found at different locations within the 
collagenous domains of COL4A3 and COL4A4 (Figure 4).
Search for modifier genes
To explain the prominent podocyte related features in the seven families, we searched for 
rare heterozygous and homozygous variants in NPHS1 and NPHS2, we did not find any 
variants in these genes in any of the seven families.
Discussion
This is the first report of COL4A3 and COL4A4 variants in a cohort of patients with a 
primary diagnosis of familial FSGS19. Previous studies have reported findings of FSGS in 
cohort of patients with collagen(IV) related kidney diseases, however the biological 
significance of these findings is unknown. Controversy exists as to whether FSGS in the 
context of collagen(IV) related kidney disease is a primary process or whether it occurs 
secondary to the GBM pathology20-23. This distinction is not clear-cut in all renal diseases 
associated with collagen(IV) abnormalities given their variable natural history and 
phenotypes. The findings from the present study seem to suggest that mutations in mature 
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GBM collagen(IV) may play a direct role in the pathogenesis of FSGS and that the 
phenotypes induced by mutations in mature GBM collagen(IV) genes may phenocopy 
primary FSGS.
The patients with COL4A3 and COL4A4 variants described in our study had significant 
proteinuria with hematuria at diagnosis. This is in contrast with AS where proteinuria and 
secondary FSGS tend to occur late in the course of the disease14. Diagnostic biopsies in our 
families had the typical findings of focal segmental sclerosis on LM and foot process 
effacement on EM but GBM morphology was not typical of AS. These findings of a mixed 
phenotype characterized by chronic progressive glomerular disease, hematuria and 
significant proteinuria at diagnosis suggest that COL4A3 and COL4A4 mutations can cause a 
wide spectrum of disease phenotypes from AS to FSGS.
The COL4A3 mutation in Family DUK6696 is most likely disease causing. Analysis of 
WES data in this family showed that the truncating compound heterozygous variant in 
COL4A3 is the only variant segregating with disease in this family. In the set of seven 
families, three of the segregating variants from two families are novel (not in dbSNP, 1000 
Genomes or NHLBI Exome Variant database). The variants described in five of the seven 
families are listed in the NHLBI Exome Variant Server (EVS) database however; these 
variants are found at very low frequencies of between 0.003 and 0.000085 in over 11,000 
chromosomes. Furthermore, four of these five variants have been previously associated with 
disease and are curated in the Leiden Open Variation Database (https://granada.lumc.nl/
LOVD2/). These data make it more plausible that these variants can cause disease. In 
addition, all the variants were predicted to be damaging by three independent in-silico 
software programs (polyphen, SIFT, mutation taster) and were all conserved in evolution, 
suggesting that they are likely to be pathogenic.
How mutations in mature GBM collagen might cause proteinuria is not understood. Altered 
permselectivity of the GBM, abnormal matrix-podocyte interactions and defective 
expression or trafficking of GBM matrix components by the podocyte are all possible 
mechanisms of disease. It is known that mutations in LAMB2 can cause FSGS24,25. This 
gene encodes for laminin β2, part of one major GBM protein, Laminin-521. Defective 
interaction of laminin-521 with podocyte integrin proteins is suggested as a possible 
mechanism of disease 24. It has also been demonstrated that α3 collagen(IV) can bind to 
integrin proteins on human podocytes via a KRGDS motif in vitro18. In our study, there 
were no consistent GBM ultrastructural findings in the families with COL4A3 and COL4A4 
variants. Conversely, podocyte foot process effacement was a constant finding and suggests 
that the observed phenotype may be due to podocyte abnormalities. Availability of data 
showing reduced staining of collagen (IV) in the glomerular basement membrane would 
have provided supportive evidence that the phenotype observed in this cohort of patients are 
due to rare variants in COL4A3 and COL4A4 genes, unfortunately this was not possible 
because of our inability to access suitable tissue for immunostaining. The previously 
described COL4A3 and COL4A4 variants found in AS and TBMN cohorts are evenly spread 
throughout the coding region of these genes. This is also the case for the collagen variants 
described in our cohort. Thus, there appears to be no particular domain or region of the α3 
or α4 proteins that might confer podocytopathy like disease expression.
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It is possible that the variable phenotypes found in this study could be due to variants in 
FSGS genes acting as disease modifiers for collagen(IV) related kidney disease. However, 
we did not find novel or known variants in genes known to cause FSGS in this cohort. In the 
families analyzed with NGS methods, we were unable to rule out other variants that may be 
pathogenic because of small pedigree size. It is therefore possible that there are yet to be 
identified podocyte/FSGS genes that may be acting as modifiers. Evidence in support of this 
is a study by Korstanje et al. that showed the degree of proteinuria in mice with a COL4A4 
mutation is dependent on their genetic background26. Conversely, it is possible that some of 
these families have mutations in currently unknown FSGS genes and COL4A3 or COL4A4 
may be functioning as modifier genes.
The clinical significance of our findings is that there is an overlap between phenotypes 
induced by COL4A3 and COL4A4 variants and familial FSGS genes; therefore screening for 
rare variants/mutations in these genes in families referred with a diagnosis of familial FSGS 
is justified for better disease definition and treatment. Furthermore exclusion of variants in 
these genes should be thoughtfully contemplated as part of a filtering algorithm in the 
analysis of WES data in familial FSGS. In the present study, WES, using a standard library 
preparation, resulted in an average coverage depth of over 60X for both genes and for 
COL4A5 (Supplementary Table 1). Current commercial testing of the coding regions of 
COL4A3, COL4A4 and COL4A5 by direct Sanger sequencing is more expensive than 
commercial WES by almost a factor of 10. Therefore with the development of robust and 
efficient bioinformatics pipelines for the analysis of WES data, NGS may represent a less 
expensive method to diagnose collagen(IV) related kidney disease. Finally this study 
emphasizes the role molecular diagnosis can play in aiding the phenotypic characterization 
of different kidney diseases and selection of appropriate treatment modalities.
Materials and Methods
Institutional Review Board approval was obtained from Duke University Medical Center 
(Durham, NC).
Clinical data
Inclusion criteria and determination of affection status are as previously reported27. Briefly, 
inclusion in this analysis required at least one individual with biopsy-proven FSGS and a 
second family member with biopsy-proven FSGS and/or ESKD. Clinical evaluation of these 
kindreds included a full family history, physical examination, urinalysis with qualitative or 
quantitative proteinuria and serum creatinine assay when appropriate. The biopsy diagnosis 
of FSGS was made based on 1) the presence of focal, and segmental areas of glomerular 
sclerosis, 2) the presence of some degree of podocyte foot process effacement as assessed by 
electron microscopy, and 3) the absence of immune deposits or other defined causes of 
glomerulonephritis as assessed by immunofluorescence or electron microscopy. Renal 
pathology reports and slides were reviewed when available for affected individuals. We also 
recorded the presence or absence of any extra renal manifestations such as hearing loss and 
ocular defects a priori and post priori.
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Whole-exome sequencing and Podocyte-exome sequencing
Whole-exome sequencing was performed on 25 families. The Illumina TruSeq kit was used 
to create a 62Mb target region exome library and a customized sequence variant analyzer 
software was used28. Podocyte-exome sequencing was performed on 38 families. An exon 
capture sequence chip containing 2,400 genes that are enriched in the podocyte was 
designed by Dr Andrey Shaw (Washington University, St Louis, MO). The gene list was 
derived from microarrays of human and mouse podocyte cell lines and glomeruli from 
human kidney biopsies. All known FSGS or chronic kidney disease genes identified in 
genome-wide association studies were added to the list. MetaCore function of GeneGO 
(GeneGo.com) was used to place all of these genes into pathways. Sequencing used a next 
generation platform and variants were called and annotated using a standardized pipeline. 
We used our standard filtering algorithm (supplementary figure 1) to identify the disease 
causing variants in the index family (Family 6696).
Direct sequencing
Genomic DNA was extracted from whole blood using the Qiagen/Puregene kit (Qiagen, 
Hilden, Germany). Mutation analysis was carried out by sequencing of both strands of all 
exons of COL4A3 and COL4A4 using exon-flanking primers; primer sequences are listed in 
supplementary tables 2 and 3. All sequences were analyzed with the Sequencher software 
(Gene Codes, Ann Arbor, MI).
Seven families were subjected to direct sequencing using exon primers for COL4A3 and 
COL4A4 (In total 70 families were studied, 25 with WES, 38 with PES and 7 with Sanger 
sequencing).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Family DUK6696 proband biopsy
(A) Masson's trichrome stain at 10X. There is segmental glomerular sclerosis in the hilar 
region with moderate interstitial fibrosis, clusters of foam cells in the interstitium, and 
tubular atrophy. (B) Periodic acid-Schiff stain of tissue from same individual.
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Figure 2. COL4A3 variants in Family DUK6696
(A) Reference chromatogram in exon 7. (B) Reference chromatogram in exon 34. (C) 
Chromatogram of heterozygous E131fsX151 variant in father, exon 7. (D) Chromatogram of 
heterozygous Q936X variant in mother, exon 34. (E, E’, E’’) Chromatograms of the three 
affected siblings showing E131fsX151 and Q936X compound heterozygous variants in 
trans.
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Figure 3. Family DUK6534 proband biopsy
A and B) The same glomerulus stained with periodic acid-Schiff (A) and hematoxylin and 
eosin (B) showing segmental sclerosis with hyalinosis (arrows) and adhesion to Bowman 
capsule. C and D) Electron microscopy from the same individual showing two different 
capillary loops. Both have localized effacement of podocyte foot processes. Area of 
basement membrane denudation with loss of podocyte cytoplasm (arrow). Glomerular 
basement membranes are slightly irregular but are of normal thickness with no lamination.
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Figure 4. COL4A3 and COL4A4 variants relative locations
(A) Cartoon of the α3 collagen(IV) protein illustrating the locations of variants described in 
this study. (B) Cartoon of the α4 collagen(IV) protein illustrating the locations of variants 
described in this study. “7S” and “NC1” refer to the canonical cysteine-rich, 25-amino acid 
N-terminal domain and the C-terminal globular non-collagenous domains respectively 
which flank the central triple helical domain. Blue diamonds represent missense variants and 
red diamonds represent frame shift and nonsense variants.
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